Noted pediatric heart surgeon Dr. Kristine Guleserian has opened up her OR, and her career to author Mark Oristano to create Surgeon’s Story Inside OR 6 With a top Pediatric Heart Surgeon. Dr. Guleserian’s life, training and work are discussed in detail, framed around the incredibly dramatic story of a heart transplant operation for a two-year old girl whose own heart was rapidly dying. Find out more at- http://surgeonsstory.com/ Media Contact: For a review copy of Surgeon’s Story or to schedule an interviewwith Mark Oristano, contact Scott Lorenz of Westwind Communications Book Marketing, 734 667 2090 scottlorenz@westwindcos.com or http://www.book-marketing-expert.com Medical Non-Fiction
Fifty-two year-old Paul McNeel, a fire chief from Leonardtown, Maryland was 37 in 1996 when a sudden health problem caused the loss of his small intestine. Almost all of it had to be surgically removed to save his life. For 13 years after that, McNeel continued to fight fires and stayed alive by feeding himself a special liquid formula through a tube that went from a port in his chest directly to his heart and into his bloodstream. Over time that feeding process called TPN or total parenteral nutrition took a toll on his body; it was damaging his liver and he began to suffer frequent and worsening infections. McNeel needed a life-saving transplant that 13 years earlier would not have been survivable. Thanks to research into improved surgical methods, better anti-rejection medications and a better understanding of the small intestine, McNeel was able to have that transplant in May 2009 at Georgetown University Hospital under the care of Thomas Fishbein, MD, executive director of the Georgetown Transplant Institute and a specialist in small bowel transplants.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52073-small-intestine-transplant-experts-hosted-by-georgetown
National blood stocks have fallen by 7% over the jubilee weekend according to latest figures from NHS Blood and Transplant (NHSBT) which today launches its annual awareness campaign, National Blood Week, to urge the public to donate blood.
During the National Blood Week recruitment drive additional appointments have been created and selected blood donor sessions have extended opening hours to give donors more flexibility to schedule a visit. Regional recruitment events will also be driving awareness and enabling people to sign up.
To launch the 2012 National Blood Week, Made In Chelsea’s Rosie Fortescue has rolled her sleeves up to recreate the heroic ‘Rosie the Riveter’ WWII poster and issue a rallying cry for new and existing blood donors to come forward. Rosie Fortescue, who shares her name with the 1940s poster girl, said: “This woman clearly knew how to get things done, and I feel honoured to become a modern day campaigner for the national blood stock build. Blood supplies are vital to the health service and every unit of blood can save or improve the lives of up to three people.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/56548-nhs-blood-transplant
Madison Taliaferro spent weeks in the hospital in 2012. After a decade of suffering from cystic fibrosis, she underwent a double lung transplant. She powered through the difficult surgery and the recovery that followed –long days of physical therapy and rehabilitation. Her parents were there. Her best friend visited from Kansas. Grandparents rotated shifts so she was never alone. But one request still lingered.
“I just wanted to see my dogs,” she remembers.
Having suffered from the effects of chronic illness for the decade prior, Madison was no stranger to long days at home, isolated from the school germs that could turn her illness into a critical condition with a single sneeze. When her friends couldn’t visit, her dogs were there. But at the hospital, they weren’t.
To view the multimedia release go to:
http://www.multivu.com/players/English/7835951-purina-family-pet-center-st-louis-childrens/
Every organ donor has the potential to save eight lives, which is the foundation of the new public awareness campaign from the Center for Organ Recovery & Education (CORE). Using multiple channels such as outdoor, television, print and radio advertising, transit wraps, a brand new website and social media, CORE is encouraging individuals to “LiVE: 8” and end the wait by signing up to become an organ and tissue donor.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7253051-center-for-organ-recovery-and-education-launches-live-8/
Unfortunately, as Graham is adopted, he doesn\\\'t have an HLA-identical sibling to act as a donor for him. So the Red Cross here in Australia searched the Bone Marrow Registries worldwide for 9 months to find a match.
Graham has a rare tissue type and a match was not found.
Thanks to generous donations of over $400,000, Graham was able to travel from his home in Melbourne, Australia to Seattle in the USA for a revolutionary, life-saving stem cell treatment in April 2008.
On Wed 6th August, he was the 8th person in the world to receive a Stem Cell Transplant using stem cells grown in the lab from an umbilical cord.
The treatment was a complete success and he is now leukaemia free.
He is back in Melbourne, recovering from the treatment but still has outstanding medical bills of $416,000.
Results from a large retrospective data analysis published in the American Journal of Transplantation (AJT) today, showed that liver transplantation patients who were treated early with Advagraf experienced a significantly increased graft survival benefit of 8% at 3 years post-transplant compared with patients treated with the current standard of care, tacrolimus immediate release (twice daily).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7451251-advagraf-prolonged-release-tacrolimus/
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
